Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01850888 · ClinicalTrials.gov registry record · NA
MIBG for Refractory Neuroblastoma and Pheochromocytoma
A NA study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
NCT01850888 is a NA study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 15 participants.
The verdict
NCT01850888, a NA study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a best available therapy/compassionate use single institution study designed to determine the palliative benefit and toxicity of 131I-MIBG in patients with progressive neuroblastoma and metastatic pheochromocytoma who are not eligible for therapies of higher priority. Patients may receive a range of doses depending on stem cell availability and tumor involvement of bone marrow. Response rate, toxicity, and time to progression and death will be evaluated.
Interventions
- DRUG G-CSF
- DRUG 131 I-Metaiodobenzylguanidine (131I-MIBG)
- DRUG Potassium iodide solution
- PROCEDURE hematopoietic stem cell infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2013-12 |
| Est. Completion | 2025-10-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01850888
The ClinicalTrials.gov registry entry for NCT01850888 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which G-CSF is the first listed.
NCT01850888 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01850888 about?
NCT01850888 is a clinical study titled "MIBG for Refractory Neuroblastoma and Pheochromocytoma". This is a best available therapy/compassionate use single institution study designed to determine the palliative benefit and toxicity of 131I-MIBG in patients with progressive neuroblastoma and metastatic pheochromocytoma who are not eligible for therapies of higher priority. Patients may receive a ...
What is the current status of trial NCT01850888?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2013-12. Estimated completion is 2025-10-20.
What interventions are being tested in trial NCT01850888?
The interventions under investigation include: G-CSF (DRUG), 131 I-Metaiodobenzylguanidine (131I-MIBG) (DRUG), Potassium iodide solution (DRUG), hematopoietic stem cell infusion (PROCEDURE).
Who is sponsoring clinical trial NCT01850888?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.